Compare IMA & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMA | MDAI |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | United States | United States |
| Employees | 17 | 65 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.3M | 60.1M |
| IPO Year | N/A | N/A |
| Metric | IMA | MDAI |
|---|---|---|
| Price | $5.95 | $1.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $16.00 | $3.00 |
| AVG Volume (30 Days) | 14.5K | ★ 790.7K |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $23.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.94 | $1.18 |
| 52 Week High | $17.50 | $3.21 |
| Indicator | IMA | MDAI |
|---|---|---|
| Relative Strength Index (RSI) | 57.46 | 35.33 |
| Support Level | $5.70 | $1.48 |
| Resistance Level | $6.06 | $1.77 |
| Average True Range (ATR) | 0.29 | 0.10 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 77.03 | 7.35 |
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
Spectral AI Inc is an AI company focused on predictive medical diagnostics. Its DeepView System uses proprietary AI algorithms to distinguish between fully damaged, partially damaged and healthy human tissue characters invisible to the naked eye, at the initial time point of wound presentation. The DeepView System delivers a binary prediction on the wound's capacity to heal or not-heal by a specified time point in the future. The company focuses on the burn indication which is supported by the BARDA PBS contract.